Chemokines, chemokine receptors and small-molecule antagonists: recent developments.

The physiological roles of chemokine receptors have expanded beyond host defense and now represent important targets for intervention in several disease indications. Chemokine receptors have joined the ranks of other members of the G-protein-coupled receptor (GPCR) family in therapeutic potential as small-molecule chemokine receptor antagonists move from discovery to the clinic. Chemokine receptors belong to the rhodopsin family of GPCRs and, as such, are expected to be closely related in structure to other Class A members. In this review, we summarize information that is pertinent to chemokine receptors as therapeutic targets, the status of low molecular weight antagonists in clinical development, molecular modeling of receptor-small-molecule interactions, and the challenges that face drug discovery and development programs.

[1]  S. Kunkel,et al.  Granulocyte-Macrophage Colony Stimulating Factor Up-Regulates CCR1 in Human Neutrophils1 , 2001, The Journal of Immunology.

[2]  T. Williams,et al.  The CC Chemokine Eotaxin (CCL11) Is a Partial Agonist of CC Chemokine Receptor 2b* , 2001, The Journal of Biological Chemistry.

[3]  J. Yang,et al.  Molecular modeling on human CCR5 receptors and complex with CD4 antigens and HIV-1 envelope glycoprotein gp120. , 2000, Acta pharmacologica Sinica.

[4]  D. Salant,et al.  Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. , 1999, The Journal of clinical investigation.

[5]  X. Wang,et al.  Allosteric regulation of CCR5 by guanine nucleotides and HIV-1 envelope. , 2001, Biochemical and biophysical research communications.

[6]  E. De Clercq,et al.  Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100 , 1998, Journal of Virology.

[7]  H. Brühl,et al.  Expression and Characterization of the Chemokine Receptors CCR2 and CCR5 in Mice1 , 2001, The Journal of Immunology.

[8]  H. Brühl,et al.  Differential Activation of CC Chemokine Receptors by AOP-RANTES* , 2000, The Journal of Biological Chemistry.

[9]  K. Matsushima,et al.  An anti-inflammatory drug, propagermanium, may target GPI-anchored proteins associated with an MCP-1 receptor, CCR2. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[10]  Hiroaki Mitsuya,et al.  Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5* , 2001, The Journal of Biological Chemistry.

[11]  R. Doms,et al.  CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. , 1999 .

[12]  J. Mallol,et al.  Comodulation of CXCR4 and CD26 in Human Lymphocytes* , 2001, The Journal of Biological Chemistry.

[13]  I. De Meester,et al.  CD26, let it cut or cut it down. , 1999, Immunology today.

[14]  M. Parmentier,et al.  A chimeric MIP‐1α/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors , 2001, Journal of leukocyte biology.

[15]  N. Aiyar,et al.  Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. , 2001, Immunology letters.

[16]  P. Loetscher,et al.  Agonistic and antagonistic activities of chemokines , 2001, Journal of leukocyte biology.

[17]  C. Power,et al.  The strategy of blocking the chemokine system to combat disease , 2000, Immunological reviews.

[18]  W. Forssmann,et al.  Hemofiltrate CC chemokines with unique biochemical properties: HCC‐1/CCL14a and HCC‐2/CCL15 , 2001, Journal of leukocyte biology.

[19]  T. Schwartz,et al.  Validation of chemokine receptors as drug targets. , 2000, Current opinion in drug discovery & development.

[20]  H. Guy,et al.  Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function* , 1999, The Journal of Biological Chemistry.

[21]  R. Horuk,et al.  Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. , 2000, European journal of pharmacology.

[22]  I. Forbes,et al.  CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound. , 2000, Bioorganic & Medicinal Chemistry Letters.

[23]  S. O. Smith,et al.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Xueqing Wang,et al.  Chemokine receptor antagonists , 2000 .

[25]  E. De Clercq,et al.  Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. , 2001, Molecular pharmacology.

[26]  M. Goldsmith,et al.  Molecular function of the CD4 D1 domain in coreceptor-mediated entry by HIV type 1. , 2000, AIDS research and human retroviruses.

[27]  R. Doms,et al.  The impact of chemokine receptor conformational heterogeneity on HIV infection. , 2001, Cellular and molecular biology.

[28]  J. Ballesteros,et al.  G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. , 2001, Current opinion in drug discovery & development.

[29]  J. Duke-Cohan,et al.  Attractin: a cub-family protease involved in T cell-monocyte/macrophage interactions. , 2000, Advances in experimental medicine and biology.

[30]  M. Baggiolini,et al.  The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3* , 2001, The Journal of Biological Chemistry.

[31]  D R Flower,et al.  Modelling G-protein-coupled receptors for drug design. , 1999, Biochimica et biophysica acta.

[32]  S. Mccombie,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element. , 2001, Bioorganic & medicinal chemistry letters.

[33]  M. Peck,et al.  A Small Molecule Antagonist of Chemokine Receptors CCR1 and CCR3 , 2000, The Journal of Biological Chemistry.

[34]  T. Schwartz,et al.  Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor* , 2001, The Journal of Biological Chemistry.

[35]  J. Lowe,et al.  Molecular basis for the species selectivity of the substance P antagonist CP-96,345. , 1993, The Journal of biological chemistry.

[36]  R. Doms,et al.  Antigenically Distinct Conformations of CXCR4 , 2001, Journal of Virology.

[37]  A. Iwama,et al.  Fractalkine shares signal sequence with TARC: gene structures and expression profiles of two chemokine genes. , 2001, Genomics.

[38]  Marc Parmentier,et al.  The Second Extracellular Loop of CCR5 Is the Major Determinant of Ligand Specificity* , 1997, The Journal of Biological Chemistry.

[39]  P. Proost,et al.  The role of CD26/DPP IV in chemokine processing. , 1999, Chemical immunology.

[40]  Marc Parmentier,et al.  Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. , 2002, Molecular biology of the cell.

[41]  J. Ballesteros,et al.  Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. , 2001, Molecular pharmacology.

[42]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[43]  C. Durinx,et al.  Kinetic Investigation of Chemokine Truncation by CD26/Dipeptidyl Peptidase IV Reveals a Striking Selectivity within the Chemokine Family* , 2001, The Journal of Biological Chemistry.

[44]  Dominique Schols,et al.  Diverging binding capacities of natural LD78β isoforms of macrophage inflammatory protein‐1α to the CC chemokine receptors 1, 3 and 5 affect their anti‐HIV‐1 activity and chemotactic potencies for neutrophils and eosinophils , 2001, European journal of immunology.

[45]  M. Montjovent,et al.  Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent Antagonist (*) , 1996, The Journal of Biological Chemistry.

[46]  D. Taub,et al.  Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor* , 1998, The Journal of Biological Chemistry.

[47]  C. Blobel,et al.  Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). , 2001, The Journal of biological chemistry.

[48]  A. Sher,et al.  Analysis of Fractalkine Receptor CX3CR1 Function by Targeted Deletion and Green Fluorescent Protein Reporter Gene Insertion , 2000, Molecular and Cellular Biology.

[49]  R. Ji,et al.  Building three-dimensional structures of HIV-1 coreceptor CCR5 and its interaction with antagonist TAK779 by comparative molecular modeling. , 2000, Acta pharmacologica Sinica.

[50]  M. Parmentier,et al.  Urokinase Plasminogen Activator and Plasmin Efficiently Convert Hemofiltrate CC Chemokine 1 into Its Active [9–74] Processed Variant1 , 2001, The Journal of Immunology.

[51]  R. Offord,et al.  Amino-terminally Modified RANTES Analogues Demonstrate Differential Effects on RANTES Receptors* , 1999, The Journal of Biological Chemistry.

[52]  Frank Diehl,et al.  Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists , 2000, The Journal of Biological Chemistry.

[53]  S. Narula,et al.  Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. , 2001, Molecular pharmacology.

[54]  M. Baggiolini,et al.  Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. , 2001, Blood.

[55]  M. Baggiolini.  Chemokines in pathology and medicine , 2001, Journal of internal medicine.